BACKGROUND: Angiogenesis is essential for cancer growth and metastasis. VEGF is a key modulator of angiogenesis and its overexpression is correlated with advanced disease and poor prognosis. Bevacizumab, a recombinant humanized anti-VEGF mAb, is the most clinically advanced anti-angiogenic agent. Although bevacizumab has received most attention for first-line treatment of advanced colorectal and non-small-cell lung cancer, there is a rapidly growing body of evidence for its efficacy in treatment of a number of other solid tumors. OBJECTIVE/ METHODS: We present the background, current status, and important ongoing trials involving the use of bevacizumab therapy. RESULTS/ CONCLUSIONS: Bevacizumab has an established role in the treatment of metastatic colon, breast, and lung cancer. Yet many questions remain on its use in other disease types and demographic groups.
BACKGROUND: Angiogenesis is essential for cancer growth and metastasis. VEGF is a key modulator of angiogenesis and its overexpression is correlated with advanced disease and poor prognosis. Bevacizumab, a recombinant humanized anti-VEGF mAb, is the most clinically advanced anti-angiogenic agent. Although bevacizumab has received most attention for first-line treatment of advanced colorectal and non-small-cell lung cancer, there is a rapidly growing body of evidence for its efficacy in treatment of a number of other solid tumors. OBJECTIVE/ METHODS: We present the background, current status, and important ongoing trials involving the use of bevacizumab therapy. RESULTS/ CONCLUSIONS:Bevacizumab has an established role in the treatment of metastatic colon, breast, and lung cancer. Yet many questions remain on its use in other disease types and demographic groups.
Authors: George Somlo; Ashkan Lashkari; William Bellamy; Todd M Zimmerman; Joseph M Tuscano; Margaret R O'Donnell; Ann F Mohrbacher; Stephen J Forman; Paul Frankel; Helen X Chen; James H Doroshow; David R Gandara Journal: Br J Haematol Date: 2011-04-26 Impact factor: 6.998
Authors: Athanassios Argiris; Michalis V Karamouzis; William E Gooding; Barton F Branstetter; Shilong Zhong; Luis E Raez; Panayiotis Savvides; Marjorie Romkes Journal: J Clin Oncol Date: 2011-02-22 Impact factor: 44.544
Authors: A Argiris; A P Kotsakis; T Hoang; F P Worden; P Savvides; M K Gibson; R Gyanchandani; G R Blumenschein; H X Chen; J R Grandis; P M Harari; M S Kies; S Kim Journal: Ann Oncol Date: 2012-08-16 Impact factor: 32.976
Authors: A Argiris; J E Bauman; J Ohr; W E Gooding; D E Heron; U Duvvuri; G J Kubicek; D M Posluszny; M Vassilakopoulou; S Kim; J R Grandis; J T Johnson; M K Gibson; D A Clump; J T Flaherty; S I Chiosea; B Branstetter; R L Ferris Journal: Ann Oncol Date: 2016-05-13 Impact factor: 32.976